Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. XRAY
XRAY logo

XRAY Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
12.885
Open
12.630
VWAP
12.71
Vol
3.46M
Mkt Cap
2.54B
Low
12.530
Amount
44.01M
EV/EBITDA(TTM)
7.50
Total Shares
199.75M
EV
4.54B
EV/OCF(TTM)
19.30
P/S(TTM)
0.69
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
Show More

Events Timeline

(ET)
2026-03-09
08:40:00
Dentsply Sirona and Siemens Healthineers Share Key Findings from Dental MRI Clinical Trial
select
2026-02-26 (ET)
2026-02-26
17:30:00
Company Board Approves Restructuring Plan, Expects $55M to $65M Charges
select
2026-02-26
16:40:00
Company Expects FY26 Revenue of $3.5B to $3.6B
select
2026-02-26
16:40:00
Company Reports Q4 Revenue of $961M
select

News

NASDAQ.COM
8.0
03-10NASDAQ.COM
Analysis of High-Yield Stocks in Pharma Sector
  • Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
  • Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
  • Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
  • Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
Fool
8.0
03-10Fool
Top High-Yield Healthcare Stocks to Consider
  • Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
  • Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
  • Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
  • Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
NASDAQ.COM
9.0
03-09NASDAQ.COM
Dentsply Sirona and Siemens Healthineers Launch Dental MRI System
  • FDA Clearance: Dentsply Sirona and Siemens Healthineers' MAGNETOM Free.Max Dental Edition has received FDA clearance, marking a significant validation of the system's potential across multiple dental specialties.
  • Clinical Trial Results: The clinical trial demonstrated the system's ability to differentiate active inflammation from healthy and scar tissue, supporting non-invasive assessments of tooth pulp vitality, thereby enhancing diagnostic accuracy and efficiency in dentistry.
  • Technological Advantages: The MAGNETOM Free.Max Dental Edition not only visualizes teeth and their positions relative to neighboring teeth and nerves but also provides dentists with a more intuitive observational tool, enhancing clinical decision-making capabilities.
  • Market Reaction: Despite the technological breakthrough from FDA clearance, Dentsply Sirona's stock price fell by 1.02% in pre-market trading on Nasdaq, indicating that market reactions to the new product still require further observation.
Newsfilter
5.0
03-09Newsfilter
First Dental-Dedicated MRI System Receives FDA Clearance
  • FDA Clearance Milestone: The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona and Siemens Healthineers, has received FDA clearance, marking a significant advancement in dental imaging technology that is expected to enhance diagnostic accuracy and efficiency in dental practices.
  • Clinical Trial Findings: The clinical trial validated the system's applicability across multiple dental specialties, including endodontics, periodontics, TMJ, tooth extraction, and orthodontics, showcasing its advantages in non-ionizing imaging that can improve treatment planning.
  • Workflow Optimization: With an average workflow time of under 20 minutes, the system significantly streamlines patient preparation, meeting the high-efficiency demands of clinical use and is anticipated to boost operational efficiency in dental clinics.
  • Training Opportunity: An advanced two-day training program on ddMRI imaging protocols and clinical procedures will be held at the University of Minnesota in April 2026, equipping clinicians with the necessary skills to effectively utilize this innovative imaging technology.
Benzinga
6.5
03-03Benzinga
Dividend Stocks Gain Favor Amid Market Turbulence
  • Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
  • Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
  • Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
  • Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
Benzinga
9.5
03-02Benzinga
Dentsply Sirona Reports Mixed Q4 Results with Earnings Miss
  • Quarterly Earnings Performance: Dentsply Sirona reported Q4 earnings of $0.27 per share, missing the analyst consensus of $0.28, indicating pressure on profitability that may affect investor confidence.
  • Sales Beat Expectations: The company achieved quarterly sales of $961 million, surpassing the analyst estimate of $927 million, suggesting resilience in market demand that could support future growth.
  • Cautious Future Outlook: Dentsply Sirona forecasts FY2026 adjusted EPS between $1.40 and $1.50, below market expectations of $1.50, reflecting a cautious stance on future profitability.
  • Stock Price Reaction: In pre-market trading, Dentsply Sirona shares fell 2.2% to $14.36, indicating a negative market reaction to the earnings report, which may impact short-term investor sentiment.
Wall Street analysts forecast XRAY stock price to rise
16 Analyst Rating
Wall Street analysts forecast XRAY stock price to rise
2 Buy
13 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
12.00
Averages
13.04
High
17.00
Current: 0.000
sliders
Low
12.00
Averages
13.04
High
17.00
Barrington
NULL
to
Outperform
maintain
$14 -> $17
AI Analysis
2026-03-02
Reason
Barrington
Price Target
$14 -> $17
AI Analysis
2026-03-02
maintain
NULL
to
Outperform
Reason
Barrington raised the firm's price target on Dentsply Sirona to $17 from $14 and keeps an Outperform rating on the shares post the Q4 report. The firm sees some evidence of the dental market stabilizing.
UBS
Kevin Caliendo
Buy
maintain
$16 -> $18
2026-03-02
Reason
UBS
Kevin Caliendo
Price Target
$16 -> $18
2026-03-02
maintain
Buy
Reason
UBS analyst Kevin Caliendo raised the firm's price target on Dentsply Sirona to $18 from $16 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XRAY
Unlock Now

Valuation Metrics

The current forward P/E ratio for DENTSPLY SIRONA Inc (XRAY.O) is 7.33, compared to its 5-year average forward P/E of 15.78. For a more detailed relative valuation and DCF analysis to assess DENTSPLY SIRONA Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
15.78
Current PE
7.33
Overvalued PE
21.11
Undervalued PE
10.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.80
Current EV/EBITDA
7.01
Overvalued EV/EBITDA
14.87
Undervalued EV/EBITDA
8.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.85
Current PS
0.61
Overvalued PS
2.64
Undervalued PS
1.05

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

todays top stocks to gain?
Intellectia · 57 candidates
Market Cap: >= 300.00MRegion: USPrice: $3.00 - $500.00Volume: >= 1,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
AAOI logo
AAOI
Applied Optoelectronics Inc
6.33B
ARLO logo
ARLO
Arlo Technologies Inc
1.68B
PRAA logo
PRAA
PRA Group Inc
605.63M
FIGS logo
FIGS
Figs Inc
2.57B
DELL logo
DELL
Dell Technologies Inc
98.13B
XRAY logo
XRAY
DENTSPLY SIRONA Inc
2.93B

Whales Holding XRAY

P
Paradigm Capital Management, Inc.
Holding
XRAY
+12.38%
3M Return
D
Dark Forest Capital Management LP
Holding
XRAY
+8.36%
3M Return
I
Invenomic Capital Management LP
Holding
XRAY
+4.99%
3M Return
C
Cooke & Bieler, L.P.
Holding
XRAY
+2.11%
3M Return
A
Ariel Investments, LLC
Holding
XRAY
+0.45%
3M Return
A
Armistice Capital LLC
Holding
XRAY
-6.08%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is DENTSPLY SIRONA Inc (XRAY) stock price today?

The current price of XRAY is 12.73 USD — it has increased 0.39

What is DENTSPLY SIRONA Inc (XRAY)'s business?

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.

What is the price predicton of XRAY Stock?

Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is13.04 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is DENTSPLY SIRONA Inc (XRAY)'s revenue for the last quarter?

DENTSPLY SIRONA Inc revenue for the last quarter amounts to 961.00M USD, increased 6.19

What is DENTSPLY SIRONA Inc (XRAY)'s earnings per share (EPS) for the last quarter?

DENTSPLY SIRONA Inc. EPS for the last quarter amounts to -0.73 USD, decreased -66.20

How many employees does DENTSPLY SIRONA Inc (XRAY). have?

DENTSPLY SIRONA Inc (XRAY) has 14000 emplpoyees as of March 12 2026.

What is DENTSPLY SIRONA Inc (XRAY) market cap?

Today XRAY has the market capitalization of 2.54B USD.